GAM
VRTX icon

Groupama Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Groupama Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.1M Buy
165,897
+2,753
+2% +$1.28M 1.08% 31
2025
Q4 		$74M Buy
163,144
+119,763
+276% +$51.6M 1.08% 24
2025
Q3 		$17M Sell
43,381
-17,916
-29% -$7.49M 0.25% 65
2025
Q2 		$27.1M Buy
61,297
+9,364
+18% +$4.32M 0.45% 48
2025
Q1 		$25.6M Buy
51,933
+8,454
+19% +$3.94M 0.51% 48
2024
Q4 		$17.4M Buy
43,479
+9,149
+27% +$4.24M 0.35% 60
2024
Q3 		$12.8M Buy
34,330
+3,739
+12% +$1.8M 0.33% 62
2024
Q2 		$14.3M Buy
30,591
+20,033
+190% +$8.7M 0.19% 77
2024
Q1 		$12.2M Sell
10,558
-14,481
-58% -$6.12M 0.22% 83
2023
Q4 		$10.2M Buy
+25,039
New +$9.25M 0.27% 71

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return